

## COVID-19 Coronavirus

### Description/Etiology

Coronavirus disease 2019 (COVID-19) is a highly infectious, potentially fatal, acute respiratory infection caused by a novel coronavirus that has been named SARS-CoV-2. The disease was first identified in December 2019 in Wuhan, a city in Hubei Province in central China, is spreading worldwide, and has been declared a pandemic. Disease severity ranges from mild respiratory illness to severe illness.

SARS-CoV-2 is closely related to SARS-CoV, which caused the severe acute respiratory syndrome (SARS) epidemic in 2003–2004. It likely evolved from a strain found in bats. Whether there was an intermediate host is unclear. Initial COVID-19 cases were linked to a seafood and live animal market in Wuhan, suggesting early cases resulted from animal-to-human transmission. Subsequent person-to-person transmission has been primarily through large respiratory droplets produced by coughing or sneezing. Indirect transmission through contact with contaminated surfaces/objects or exposure to elevated aerosol concentrations in enclosed spaces appears to have been responsible for some infections; however, person-to-person airborne transmission over long distances is unlikely. Transmission by asymptomatic carriers appears possible.

Signs/symptoms develop after an average incubation period of 2–7 days. The most common symptoms are fever, dry cough, and shortness of breath. Complications include respiratory complications (e.g., acute respiratory distress syndrome [ARDS], respiratory failure), infectious complications (e.g., secondary infection, sepsis, septic shock), cardiac complications (e.g., acute cardiac injury, arrhythmias), acute kidney injury, liver dysfunction, multiple organ dysfunction/failure, complications of critical illness (e.g., ventilator-associated pneumonia, venous thromboembolism, catheter-related bloodstream infection, pressure injury, stress ulcers), and mortality.

There is no specific antiviral treatment or preventive vaccine. Treatment involves implementing infection control measures and providing supportive care. Infection control measures include implementing standard precautions, contact precautions, and droplet precautions during all patient care; using airborne precautions for aerosol-generating procedures (e.g., intubation, open suctioning of respiratory tract); using appropriate personal protective equipment (i.e., N95 or higher-level respirator [facemask is acceptable alternative if respirators are not available], eye/face protection (goggles or face shield), long-sleeved gown, and gloves); ensuring rapid, safe triage of symptomatic patients; promoting patient respiratory hygiene, cough etiquette, and hand hygiene; appropriately placing and isolating patients; and managing visitor access/movement. Supportive care may include symptomatic relief (e.g., antipyretics for fever), respiratory support, fluid management, empiric antimicrobials for sepsis, close patient monitoring for clinical deterioration, and prophylactic measures to reduce risk of complications.

### Facts and Figures

A cluster of acute respiratory illness, now known to have been the first cases of COVID-19, first occurred in Wuhan, a city in Hubei Province in central China in December 2019.

As of April 13, 2020, there were 1,870,076 confirmed cases and 116,052 deaths worldwide. Of these, 558,526 cases and 22,146 deaths occurred in the United States. Other countries with high numbers of reported cases/deaths include Spain (169,496 cases and 17,489

#### Author

Tanja Schub, BS

Cinahl Information Systems, Glendale, CA

#### Reviewers

Julie Brown

Nurse Excellent

#### Editor

Diane Hanson, MM, BSN, RN, FNAP

March 27, 2020

deaths), Italy (156,363 cases and 19,899 deaths), and France (133,672 cases and 14,412 deaths). China, where the disease first originated, has 83,213 cases and 3,345 deaths reported (World Health Organization, 2020b, Centers for Disease Control and Prevention, 2020c)

The first 2 cases in the United States were reported on January 14, 2020. Of the 558,526 cases reported in the United States as of April 13, 2020, 2,138 were classified as travel-related, 10,956 were the result of close contact with infected persons in the United States, and 446,071 were under investigation. (Centers for Disease Control and Prevention, 2020c)

Although most patients (81%) develop mild illness, 14% develop severe disease that requires hospitalization and oxygen support, and 5% require ICU admission. (World Health Organization, 2020a)

The average infected person transmits the virus to 2.2-3.6 other people. (Li et al., 2020; Lai et al, 2020)

## **Risk Factors**

Risk factors for developing COVID-19 include residing in or traveling to an area with widespread sustained transmission of SARS-CoV-2; and living with, being intimate partner of, providing care to, or having other close contact (i.e., being within approximately 6 feet/2 m) for a prolonged period or having direct contact with direct secretions) with a person with COVID-19.

Possible risk factors for severe illness include older age, underlying medical conditions (e.g., cardiovascular disease, chronic respiratory disease, diabetes mellitus, hypertension, cancer, liver disease, immunocompromise, or pregnancy), secondary infection, elevated inflammatory indicators (e.g., C-reactive protein), and history of smoking.

## **Signs and Symptoms/Clinical Presentation**

Signs and symptoms develop after an average incubation period of 2-7 days. Common manifestations include fever (may be prolonged or intermittent), dry cough, muscle aches, fatigue, and shortness of breath. Less common signs and symptoms include sore throat, headache, confusion, cough with sputum production and/or hemoptysis, chest pain, diarrhea, nausea, and vomiting. Lab abnormalities may include leukopenia, leukocytosis, lymphopenia, prolonged prothrombin time, and elevated liver enzymes.

Clinical presentation tends to be less severe in children than in adults. Signs and symptoms are typically limited to fever and cough.

## **Assessment**

### › **Patient History**

- Ask about recent travel, especially to areas of sustained, widespread COVID-19 transmission
- Inquire about history of close contact with a confirmed COVID-19 patient

### › **Physical Findings of Particular Interest**

- Fever has been reported in 83–99% of patients

### › **Laboratory Tests That May Be Ordered**

- Blood tests such as CBC, blood cultures, liver enzymes, lactate dehydrogenase, muscle enzymes, and C-reactive protein
- Routine tests for other respiratory pathogens including influenza virus
- Real-time RT-PCR testing using upper respiratory tract specimens (nasopharyngeal swab and possibly oropharyngeal swab) and lower respiratory tract specimens, if available, to diagnose

### › **Other Diagnostic Tests/Studies**

- Chest x-ray or computed tomography (CT) scan to assess for bilateral involvement (more than 75% of cases) with multiple areas of consolidation and ground glass opacities

## **Treatment Goals**

### › **Implement Infection Control Measures to Prevent Further Disease Transmission**

- Apply standard and transmission-based precautions (droplet or airborne). Use airborne precautions for aerosol-generating procedures
- Perform hand hygiene (using alcohol-based hand rub containing at least 60% alcohol or by washing hands with soap and water for at least 20 seconds) before and after all patient contact, contact with potentially infectious material, before putting on PPE, and after removing PPE

- Use PPE including an N95 or higher-level respirator (facemask is acceptable alternative if respirators are not available), eye/face protection (goggles or face shield), long-sleeved gown, and gloves



**Figure 1:** PPE. Copyright© 2020, EBSCO Information Services.



**Figure 2:** NIOSH-Approved N95 Respirator. Copyright ©2016, EBSCO Information Services

- If possible, place admitted patient in single-person room with dedicated bathroom and closed door. Avoid room transfers during patient stay, if possible
- Limit patient transport/movement outside room. Perform procedures/tests in room, when possible
  - Place facemask on patients that require transportation out of room. Ensure the transporter wears a facemask for anything more than a brief encounter
- Avoid/minimize aerosol-generating procedures. If one must be performed, apply airborne precautions. Limit attendees to health care providers essential for procedure and ensure all present wear N95 or higher-level respirator and other

appropriate PPE. Do not allow visitors to be present. Ideally perform procedure in Airborne Infection Isolation Room (AIIR)

- Manage visitor access/movement. Ensure visitors perform hand hygiene and follow respiratory hygiene and cough etiquette precautions, screen for signs/symptoms before entry, inform about need to wear PPE, limit and screen visitors to most vulnerable patients, encourage alternatives to in-person visits (e.g., video calls), and maintain record of all persons entering room
- Ensure appropriate cleaning and surface decontamination of room after patient discharge or transfer from room

› **Provide Supportive Care to Promote Optimum Physiologic Status and Reduce Risk of Complications**

- Closely monitor vital signs, breath sounds, pulse oximetry, ABG values, and respiratory and fluid status
- Provide symptomatic relief (e.g., antipyretics for fever), as ordered
- Initiate supplemental oxygen for patients with respiratory distress, hypoxemia, or shock
  - For patients with acute respiratory distress syndrome (ARDS), assist with endotracheal intubation, ensuring adherence to airborne precautions during procedure, and initiate/monitor mechanical ventilation
  - Initiate prone ventilation for 12-16 hours per day, if ordered
  - Assist with extracorporeal membrane oxygenation (ECMO), if ordered
- Closely monitor patient for signs of clinical deterioration, including rapidly progressive respiratory failure and sepsis. Initiate prescribed supportive care measures immediately
- Initiate prophylactic measures to prevent complications of critical illness
  - Use ventilator weaning protocols, minimize sedation, position patient semi-recumbent, use a closed suctioning system, periodically drain and discard tube condensate, and use a new circuit for each patient to reduce risk of ventilator-associated pneumonia
  - Administer prescribed anticoagulants (e.g., low-molecularweight heparin), as ordered, and/or apply intermittent pneumatic compression devices to reduce risk of venous thromboembolism
  - Use sterile technique during IV catheter insertion and remove when no longer needed to reduce risk of catheter-related bloodstream infection
  - Turn patient every 2 hours to reduce risk of pressure injury
  - Provide early enteral nutrition and administer prescribed histamine-2 blocker or proton pump inhibitor, as ordered, to reduce risk of stress ulcer
  - Encourage early mobilization, as patient condition permits, to reduce ICU-related weakness
- Monitor patient for development of septic shock. Assist with resuscitation efforts, as ordered, including administering antimicrobial therapy, IV fluids (i.e., bolus normal saline or Ringer’s lactate), and vasopressors (e.g., norepinephrine, EPINEPHrine)

› **Provide Emotional Support and Educate**

- Assess patient/family member anxiety level and coping ability; provide emotional support and educate about COVID-19, potential complications, supportive care benefits, and individualized prognosis
- As appropriate, request referral to the hospital chaplain, a clergy person, or a mental health clinician for supportive counseling on coping with a potentially life-threatening condition

## **Food for Thought**

- › Most human coronaviruses cause mild respiratory infections, such as the common cold. However, in recent years, epidemics of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), resulted in more than 10,000 total cases and mortality rates of 10% and 37%, respectively (Gerber et al., 2016; Huang et al., 2020)
- › Although SARS-CoV-2 has been found in patient stools, whether fecal-oral transmission is possible is unclear (Lai et al., 2020; Tesini, 2020)
- › A number of possible treatments for COVID-19 are currently under investigation, including the antimalarial drug chloroquine (World Health Organization, 2020e)

## **Red Flags**

- › The appropriate health department should be notified immediately of patients with suspected COVID-19. Public health staff will help determine if testing is warranted and coordinate testing
- › Health care clinicians caring for patients with known or suspected COVID-19 must immediately implement standard precautions, contact precautions, and droplet precautions, and apply airborne precautions for aerosol-generating procedures

- › PPE must be used during all patient care activities. This includes an N95 or higher-level respirator (facemask is acceptable alternative if respirators are not available), eye/face protection (goggles or face shield), long-sleeved gown, and gloves
- › Patient isolation measures, whether in the home or in a health care setting, are important to prevent spread of COVID-19
- › Patients with mild clinical presentation may experience clinical deterioration during the second week of illness. Patient monitoring for progression to lower respiratory tract disease is imperative

## What Do I Need to Tell the Patient/Patient's Family?

- › Provide information about signs and symptoms of COVID-19, the most common of which are fever, dry cough, and shortness of breath
- › Teach patients ways to protect themselves from contracting COVID-19, such as by:
  - Frequent handwashing with soap and water for at least 20 seconds or hand sanitizer containing at least 60% alcohol, especially after contact with ill people or being in a public place
  - Avoiding touching face, eyes, and mouth with potentially contaminated hands
  - Cleaning and disinfecting frequently touched surfaces (e.g., countertops, tables, doorknobs, phones) daily
  - Avoiding close contact with people with acute respiratory infections
  - Social distancing (i.e., avoiding congregate settings and mass gatherings, and maintaining distance of approximately 6 feet/2 meters from others when possible) in areas of community spread
  - Wearing a facemask when outside the home
- › Educate about strategies for early detection and preventing further transmission, such as:
  - Isolation, quarantine, controlled travel, active monitoring, self-monitoring with public health supervision, self-monitoring, self-observation, or social distancing depending on assessed risk level and whether symptoms are present
  - Seeking health care advice if signs and symptoms (e.g., fever or cough) develop to determine if medical evaluation is needed
  - Protecting others if you are potentially infected by staying home, practicing respiratory hygiene and cough etiquette, and wearing a facemask while around others



**Figure 3:** Cough Etiquette. Copyright© 2020, EBSCO Information Services.

- › Provide patient education resources, if available, to reinforce verbal education



## References

1. Cai, J., Sun, W., Huang, J., Gamber, M., Wu, J., & He, G. (2020). Indirect virus transmission in cluster of covid-19 cases, Wenzhou, China, 2020. *Emerging Infectious Diseases*, 26(6). doi:10.3201/eid2606.200412 (R)
2. Cascella, M., Rajnik, M., Cuomo, A., Dullebohn, S. C., & Di Napoli, R. (2020, March 8). Features, Evaluation and Treatment Coronavirus (COVID-19). *StatPearls [Internet]*. Treasure Island, FL: StatPearls Publishing. (GI)
3. Centers for Disease Control and Prevention. (2020, March 28). Coronavirus Disease 2019 (COVID-19): Clean & Disinfect: Interim Recommendations for US Households with Suspected/Confirmed Coronavirus Disease 2019. Retrieved April 13, 2020, from [https://www.cdc.gov/coronavirus/2019-ncov/prepare/cleaning-disinfection.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcommunity%2Fhome%2Fcleaning-disinfection.html](https://www.cdc.gov/coronavirus/2019-ncov/prepare/cleaning-disinfection.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcommunity%2Fhome%2Fcleaning-disinfection.html) (G)
4. Centers for Disease Control and Prevention. (2020, April 8). Coronavirus Disease 2019 (COVID-19): How to Protect Yourself. Retrieved April 13, 2020, from <https://www.cdc.gov/coronavirus/2019-ncov/prepare/prevention.html> (G)
5. Centers for Disease Control and Prevention. (2020, April 12). Coronavirus Disease 2019 (COVID-19): cases in the U.S. Retrieved April 13, 2020, from <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html> (GI)
6. Centers for Disease Control and Prevention. (2020, March 14). Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). Retrieved April 13, 2020, from [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fclinical-criteria.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fclinical-criteria.html) (G)
7. Centers for Disease Control and Prevention. (2020, April 6). Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Retrieved April 13, 2020, from <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html> (G)
8. Centers for Disease Control and Prevention. (2020, April 8). Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19). Retrieved April 13, 2020, from <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html> (G)
9. Centers for Disease Control and Prevention. (2020, April 8). Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings. Retrieved April 13, 2020, from [https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhosp%2Finfection-control/control-recommendations.html](https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhosp%2Finfection-control/control-recommendations.html) (G)
10. Centers for Disease Control and Prevention. (2020, March 30). Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential Coronavirus Disease 2019 (COVID-19) Exposures: Geographic Risk and Contacts of Laboratory-confirmed Cases. Retrieved April 13, 2020, from <https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html> (G)
11. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet (London, England)*, 395(10223), 507-513. doi:10.1016/S0140-6736(20)30211-7 (R)
12. Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., & Drosten, C. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*, 25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045 (R)
13. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. (2020). The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*, *Advanced online publication*. doi:10.1038/s41564-020-0695-z (RV)
14. Gerber, S. I., & Anderson, L. J. (2016). Coronaviruses. In L. Goldman & A. I. Schafer (Eds.), *Goldman-Cecil medicine* (25th ed., Vol. 2, pp. 2199-2201). Philadelphia, PA: Elsevier Saunders. (GI)
15. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*, 395(10223), 497-506. doi:10.1016/S0140-6736(20)30183-5 (R)
16. Lai, C. -C., Shih, T. -P., Ko, W. -C., Tang, H. -J., & Hsueh, P. -R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents*, 55(3). doi:10.1016/j.ijantimicag.2020.105924 (RV)
17. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., & Feng, Z. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *New England Journal of Medicine*, *Advanced online publication*. doi:10.1056/NEJMoa2001316 (R)
18. Liu, W., Tao, Z. -W., Lei, W., Ming-Li, Y., Kui, L., Ling, Z., & Yi, H. (2020). Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chinese Medical Journal*, *Advanced online publication*. doi:10.1097/CM9.0000000000000775 (R)
19. Paraskevis, D., Kostaki, E. G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., & Tsiodras, S. (2020). Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. *Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases*, 79(104212). doi:10.1016/j.meegid.2020.104212 (R)
20. Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., & Hoelscher, M. (2020). Transmission of 2019-ncov infection from an asymptomatic contact in Germany. *New England Journal of Medicine*, 382(10), 970-971. doi:10.1056/NEJMc2001468 (C)
21. Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine*, *Advanced online publication*. doi:10.1007/s00134-020-05991-x (R)
22. Tang, B., Bragazzi, N. L., Li, Q., Tang, S., Xiao, Y., & Wu, J. (2020). An updated estimation of the risk of transmission of the novel coronavirus (2019-nCoV). *Infectious Disease Modelling*, 5, 248-255. doi:10.1016/j.idm.2020.02.001 (R)
23. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA: Journal of the American Medical Association*, *Advanced online publication*. doi:10.1001/jama.2020.1585 (R)
24. World Health Organization. (2020, March 19). Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. Retrieved April 13, 2020, from [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected) (G)
25. World Health Organization. (2020, March 23). Coronavirus disease 2019 (COVID-19) Situation Report – 63. Retrieved April 13, 2020, from [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200323-sitrep-63-covid-19.pdf?sfvrsn=d97cb6dd\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200323-sitrep-63-covid-19.pdf?sfvrsn=d97cb6dd_2) (GI)
26. World Health Organization. (2020, March 19). Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. Interim guidance. Retrieved April 13, 2020, from [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125) (G)
27. World Health Organization. (2020, March 19). Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance. Retrieved April 13, 2020, from <https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117> (G)
28. World Health Organization. (2020, March 13). WHO R&D Blueprint. COVID-1. Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection. Retrieved April 13, 2020, from <https://www.who.int/blueprint/priority-diseases/key-action/RD-Blueprint-expert-group-on-CQ-call-Mar-13-2020.pdf?ua=1> (RV)